{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:58:48Z","timestamp":1791100728881,"version":"4.1.0"},"reference-count":32,"publisher":"American Association for Cancer Research (AACR)","issue":"14","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We have described recently the Ets family transcription factor, ERM\/ETV5, specifically up-regulated in endometrioid endometrial carcinoma (EEC) and associated with myometrial infiltration. Ets family members have been correlated to tumor progression by up-regulating the expression of matrix-degrading proteases. In the present study, we investigated the possibility that in EEC, ERM\/ETV5 may act by inducing the expression of genes involved in extracellular matrix remodeling. Unraveling the molecular events associated with the initiation of tumor invasion would represent an obvious improvement for EEC patients. The overexpression of ERM\/ETV5 induced scattering in the endometrial cancer cell line Hec-1A, correlating to increased matrix metalloproteinase-2 (MMP-2) gelatinase activity. Both chromatin immunoprecipitation and reversion experiments with RNA interference and specific MMP-2 inhibitor showed a functional link between ERM\/ETV5 overexpression and MMP-2 activation. The increased MMP-2 activity associated with overexpressed ERM\/ETV5 in a mouse model conferred invasive capacity to endometrial tumors. Orthotopically implanted overexpressing ERM\/ETV5 tumors presented a more aggressive and infiltrative pattern of myometrial invasion. Finally, the specific localization of ERM\/ETV5 and MMP-2 at the invasive front of myometrial infiltrating human endometrial carcinomas further reinforced the hypothesis of a role for ERM\/ETV5 in the early steps of endometrial dissemination. Taken together, these results lead us to propose that in EEC, ERM\/ETV5 acts through MMP-2 gelatinolytic activity to confer invasive capabilities, associated with an initial switch to myometrial infiltration. They also postulate ERM\/ETV5 as a valuable marker for patient stratification and a transcription pathway that should be evaluated for therapies specifically targeting the initial steps of EEC dissemination. [Cancer Res 2007;67(14):6753\u20139]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-4487","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T19:07:57Z","timestamp":1184699277000},"page":"6753-6759","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["ERM\/ETV5 Up-regulation Plays a Role during Myometrial Infiltration through Matrix Metalloproteinase-2 Activation in Endometrial Cancer"],"prefix":"10.1158","volume":"67","author":[{"given":"Marta","family":"Monge","sequence":"first","affiliation":[{"name":"1Research Institute Vall d'Hebron University Hospital; Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Colas","sequence":"additional","affiliation":[{"name":"1Research Institute Vall d'Hebron University Hospital; Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Doll","sequence":"additional","affiliation":[{"name":"1Research Institute Vall d'Hebron University Hospital; Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"1Research Institute Vall d'Hebron University Hospital; Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gil-Moreno","sequence":"additional","affiliation":[{"name":"2Gynecological Oncology and"},{"name":"5Faculty of Medicine, Autonoma University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Planaguma","sequence":"additional","affiliation":[{"name":"1Research Institute Vall d'Hebron University Hospital; Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Quiles","sequence":"additional","affiliation":[{"name":"1Research Institute Vall d'Hebron University Hospital; Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonia","family":"Arbos","sequence":"additional","affiliation":[{"name":"1Research Institute Vall d'Hebron University Hospital; Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Garcia","sequence":"additional","affiliation":[{"name":"3Pathology, Vall d'Hebron University Hospital;"},{"name":"5Faculty of Medicine, Autonoma University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Castellvi","sequence":"additional","affiliation":[{"name":"3Pathology, Vall d'Hebron University Hospital;"},{"name":"5Faculty of Medicine, Autonoma University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Llaurado","sequence":"additional","affiliation":[{"name":"1Research Institute Vall d'Hebron University Hospital; Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Rigau","sequence":"additional","affiliation":[{"name":"1Research Institute Vall d'Hebron University Hospital; Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafid","family":"Alazzouzi","sequence":"additional","affiliation":[{"name":"1Research Institute Vall d'Hebron University Hospital; Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Xercavins","sequence":"additional","affiliation":[{"name":"2Gynecological Oncology and"},{"name":"5Faculty of Medicine, Autonoma University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Alameda","sequence":"additional","affiliation":[{"name":"4Pathology Department, Hospital del Mar; and"},{"name":"5Faculty of Medicine, Autonoma University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Reventos","sequence":"additional","affiliation":[{"name":"1Research Institute Vall d'Hebron University Hospital; Departments of"},{"name":"5Faculty of Medicine, Autonoma University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Abal","sequence":"additional","affiliation":[{"name":"1Research Institute Vall d'Hebron University Hospital; Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,7,17]]},"reference":[{"key":"2022061623211517400_B1","unstructured":"Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol\u20081997; 81: 228\u201332."},{"key":"2022061623211517400_B2","doi-asserted-by":"crossref","unstructured":"Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst\u20081996; 88: 1127\u201335.","DOI":"10.1093\/jnci\/88.16.1127"},{"key":"2022061623211517400_B3","doi-asserted-by":"crossref","unstructured":"Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Hum Pathol\u20081998; 29: 924\u201331.","DOI":"10.1016\/S0046-8177(98)90197-6"},{"key":"2022061623211517400_B4","unstructured":"Sherman ME, Sturgeon S, Brinton LA, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol\u20081997; 10: 963\u20138."},{"key":"2022061623211517400_B5","unstructured":"Abal M, Planaguma J, Gil-Moreno A, et al. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors. Histol Histopathol\u20082006; 21: 197\u2013204."},{"key":"2022061623211517400_B6","doi-asserted-by":"crossref","unstructured":"Planaguma J, Diaz-Fuertes M, Gil-Moreno A, et al. A differential gene expression profile reveals overexpression of RUNX1\/AML1 in invasive endometrioid carcinoma. Cancer Res\u20082004; 64: 8846\u201353.","DOI":"10.1158\/0008-5472.CAN-04-2066"},{"key":"2022061623211517400_B7","doi-asserted-by":"crossref","unstructured":"Planaguma J, Abal M, Gil-Moreno A, et al. Up-regulation of ERM\/ETV5 correlates with the degree of myometrial infiltration in endometrioid endometrial carcinoma. J Pathol\u20082005; 207: 422\u20139.","DOI":"10.1002\/path.1853"},{"key":"2022061623211517400_B8","doi-asserted-by":"crossref","unstructured":"de Launoit Y, Baert JL, Chotteau-Lelievre A, et al. The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta\u20082006; 1766: 79\u201387.","DOI":"10.1016\/j.bbcan.2006.02.002"},{"key":"2022061623211517400_B9","doi-asserted-by":"crossref","unstructured":"Graves BJ, Petersen JM. Specificity within the ets family of transcription factors. Adv Cancer Res\u20081998; 75: 1\u201355.","DOI":"10.1016\/S0065-230X(08)60738-1"},{"key":"2022061623211517400_B10","unstructured":"Kaya M, Yoshida K, Higashino F, et al. A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene\u20081996; 12: 221\u20137."},{"key":"2022061623211517400_B11","doi-asserted-by":"crossref","unstructured":"Takai N, Miyazaki T, Fujisawa K, Nasu K, Miyakawa I. Expression of c-Ets1 is associated with malignant potential in endometrial carcinoma. Cancer\u20082000; 89: 2059\u201367.","DOI":"10.1002\/1097-0142(20001115)89:10<2059::AID-CNCR5>3.0.CO;2-3"},{"key":"2022061623211517400_B12","doi-asserted-by":"crossref","unstructured":"Di Nezza LA, Misajon A, Zhang J, et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer\u20082002; 94: 1466\u201375.","DOI":"10.1002\/cncr.10355"},{"key":"2022061623211517400_B13","doi-asserted-by":"crossref","unstructured":"Abal M, Bras-Goncalves R, Judde JG, et al. Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene\u20082004; 23: 1737\u201344.","DOI":"10.1038\/sj.onc.1207299"},{"key":"2022061623211517400_B14","doi-asserted-by":"crossref","unstructured":"Arbos MA, Ferrando JM, Quiles MT, et al. Improved surgical mesh integration into the rat abdominal wall with arginine administration. Biomaterials\u20082006; 27: 758\u201368.","DOI":"10.1016\/j.biomaterials.2005.06.027"},{"key":"2022061623211517400_B15","doi-asserted-by":"crossref","unstructured":"De Hauwer C, Camby I, Darro F, et al. Dynamic characterization of glioblastoma cell motility. Biochem Biophys Res Commun\u20081997; 232: 267\u201372.","DOI":"10.1006\/bbrc.1997.6291"},{"key":"2022061623211517400_B16","doi-asserted-by":"crossref","unstructured":"Aglund K, Rauvala M, Puistola U, et al. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol\u20082004; 94: 699\u2013704.","DOI":"10.1016\/j.ygyno.2004.06.028"},{"key":"2022061623211517400_B17","doi-asserted-by":"crossref","unstructured":"Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J\u20081999; 13: 781\u201392.","DOI":"10.1096\/fasebj.13.8.781"},{"key":"2022061623211517400_B18","doi-asserted-by":"crossref","unstructured":"Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell\u20082000; 103: 481\u201390.","DOI":"10.1016\/S0092-8674(00)00139-2"},{"key":"2022061623211517400_B19","doi-asserted-by":"crossref","unstructured":"Kotyza J, Pesek M, Puzman P, Havel D. Progelatinase B\/matrix metalloproteinase-9 proenzyme as a marker of pleural inflammation. Exp Lung Res\u20082004; 30: 297\u2013309.","DOI":"10.1080\/01902140490276393"},{"key":"2022061623211517400_B20","doi-asserted-by":"crossref","unstructured":"Wasylyk C, Gutman A, Nicholson R, Wasylyk B. The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J\u20081991; 10: 1127\u201334.","DOI":"10.1002\/j.1460-2075.1991.tb08053.x"},{"key":"2022061623211517400_B21","doi-asserted-by":"crossref","unstructured":"Gutman A, Wasylyk B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J\u20081990; 9: 2241\u20136.","DOI":"10.1002\/j.1460-2075.1990.tb07394.x"},{"key":"2022061623211517400_B22","unstructured":"Nerlov C, Rorth P, Blasi F, Johnsen M. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene\u20081991; 6: 1583\u201392."},{"key":"2022061623211517400_B23","doi-asserted-by":"crossref","unstructured":"Ozaki I, Mizuta T, Zhao G, et al. Induction of multiple matrix metalloproteinase genes in human hepatocellular carcinoma by hepatocyte growth factor via a transcription factor Ets-1. Hepatol Res\u20082003; 27: 289\u2013301.","DOI":"10.1016\/S1386-6346(03)00268-7"},{"key":"2022061623211517400_B24","doi-asserted-by":"crossref","unstructured":"Horiuchi S, Yamamoto H, Min Y, et al. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol\u20082003; 200: 568\u201376.","DOI":"10.1002\/path.1387"},{"key":"2022061623211517400_B25","doi-asserted-by":"crossref","unstructured":"Hahne JC, Okuducu AF, Kaminski A, et al. Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene\u20082005; 24: 5384\u20138.","DOI":"10.1038\/sj.onc.1208761"},{"key":"2022061623211517400_B26","doi-asserted-by":"crossref","unstructured":"Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer\u20082003; 2: 29.","DOI":"10.1186\/1476-4598-2-29"},{"key":"2022061623211517400_B27","doi-asserted-by":"crossref","unstructured":"Taguchi K, Yoshida K, Sasaki F, Fujinaga K. Two transcription factors, E1AF and N-myc, correlate with the invasiveness of neuroblastoma cell lines. Jpn J Cancer Res\u20081997; 88: 394\u2013400.","DOI":"10.1111\/j.1349-7006.1997.tb00395.x"},{"key":"2022061623211517400_B28","doi-asserted-by":"crossref","unstructured":"Hanzawa M, Shindoh M, Higashino F, et al. Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis\u20082000; 21: 1079\u201385.","DOI":"10.1093\/carcin\/21.6.1079"},{"key":"2022061623211517400_B29","doi-asserted-by":"crossref","unstructured":"Nishikawa A, Iwasaki M, Akutagawa N, et al. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential. Gynecol Oncol\u20082000; 79: 256\u201363.","DOI":"10.1006\/gyno.2000.5944"},{"key":"2022061623211517400_B30","doi-asserted-by":"crossref","unstructured":"Fidler IJ, Naito S, Pathak S. Orthotopic implantation is essential for the selection, growth, and metastasis of human renal cell cancer in nude mice [corrected]. Cancer Metastasis Rev\u20081990; 9: 149\u201365.","DOI":"10.1007\/BF00046341"},{"key":"2022061623211517400_B31","doi-asserted-by":"crossref","unstructured":"Graesslin O, Cortez A, Uzan C, et al. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int J Gynecol Cancer\u20082006; 16: 1911\u20137.","DOI":"10.1111\/j.1525-1438.2006.00717.x"},{"key":"2022061623211517400_B32","doi-asserted-by":"crossref","unstructured":"Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature\u20082007; 446: 765\u201370.","DOI":"10.1038\/nature05760"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/14\/6753\/2569709\/6753.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/14\/6753\/2569709\/6753.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T22:48:58Z","timestamp":1655419738000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/14\/6753\/533149\/ERM-ETV5-Up-regulation-Plays-a-Role-during"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,15]]},"references-count":32,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2007,7,17]]},"published-print":{"date-parts":[[2007,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-4487","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22368603","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368600.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368606","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368609","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368603.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368600","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368606.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368609.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6496026.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6496026","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,15]]}}}